Prognostic Role of the Ubiquitin Proteasome System in Clear Cell Renal Cell Carcinoma: A Bioinformatic Perspective

Guo, Hongda; Li, Yan; Liu, Yaxiao; Chen, Lipeng; Gao, Zhengdong; Zhang, Lekai; Zhou, Nan; Guo, Hu; Shi, Benkang

doi:10.7150/jca.53760

Cited by 7 publications

(2 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, Jiang et al (2017[ 66 ]) studied the mechanism by which immune evasion affects the response to treatment of NPC. BTZ downregulated IFNγ-induced IDO expression via inhibition of JAK/STAT1 signaling pathway and promoted IkB-α phosphorylation-ubiquitination to release NF-kB from IkB-α (Guo et al, 2021[ 51 ]).…”

Section: Btz Implementation In Solid Tumorsmentioning

confidence: 99%

Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications

Alwahsh

Farhat

Talhouni

et al. 2023

EXCLI Journal; 22:Doc146; ISSN 1611-2156

View full text Add to dashboard Cite

Bortezomib (BTZ) is a first-in-class reversible and selective proteasome inhibitor. It inhibits the ubiquitin proteasome pathway that leads to the degradation of many intracellular proteins. Initially, BTZ was FDA approved for the treatment of refractory or relapsed multiple myeloma (MM) in 2003. Later, its usage was approved for patients with previously untreated MM. In 2006, BTZ was approved for the treatment of relapsed or refractory Mantle Cell Lymphoma (MCL) and, in 2014, for previously untreated MCL. BTZ has been extensively studied either alone or in combination with other drugs for the treatment of different liquid tumors especially in MM. However, limited data evaluated the efficacy and safety of using BTZ in patients with solid tumors. In this review, we will discuss the advanced and novel mechanisms of action of BTZ documented in MM, solid tumors and liquid tumors. Moreover, we will shed the light on the newly discovered pharmacological effects of BTZ in other prevalent diseases.

show abstract

Section: Btz Implementation In Solid Tumorsmentioning

confidence: 99%

Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications

Alwahsh

Farhat

Talhouni

et al. 2023

EXCLI Journal; 22:Doc146; ISSN 1611-2156

View full text Add to dashboard Cite

show abstract

“…TRIM21-deficient mice that developed dermatitis exhibited impairments in renal filtration and albuminuria. 92 Proteasomal disturbances occur in a variety of kidney dysfunctions, [93][94][95] but the potential TRIM21 engagement in this process remains largely obscure.…”

Section: Trim21 Proteasome Initiation and Autophagosome-like Structuresmentioning

confidence: 99%

Presence and possible impact of Fcγ receptors on resident kidney cells in health and disease

2022

View full text Add to dashboard Cite

Fcγ receptors (FcγRs) bind the Fc fragment of immunoglobulin G (IgG), mostly after IgG opsonizes a bacterial or viral antigen or danger/damage‐associated molecule. Consequently, classic FcγRs initiate phagocytosis of the IgG–antigen immune complex and stimulate an immune reaction against the threat. Signals from activating FcγRs (FcγRI, FcγRIIa/c, FcγRIIIa/b) are balanced by inhibitory FcγRIIb and likely also by two FcR‐like proteins (FCRL4 and FCRL5). The neonatal Fc receptor (FcRn) recirculates IgG and increases its half‐life. The last FcγR that has been identified in humans, tripartite motif‐containing protein 21 (TRIM21), acts toward pathogen destruction via the proteasomal or autophagic pathway. The expression of FcγRs occurs almost exclusively in immune cells. However, podocytes, key cells in the glomerular filtration barrier, also possess several features of an immune cell and express receptors for IgG. The presence of FcγRs in glomeruli was analyzed in the Human Protein Atlas project. FcγR occurrence in whole glomeruli or in particular resident kidney cells was also showed in a few original articles. In human podocytes only FcRn has been studied extensively, and the presence and role of other FcγRs remain obscure. Research on the genetic background of kidney diseases revealed a connection between FcγRs and several nephropathies. Investigations of FcγR expression in podocytes appear to be of great clinical importance. The present review discusses the latest literature on FcγRs in kidney cells (especially podocytes), with an emphasis on their involvement in kidney health and disease.

show abstract

Amino Acid‐Starved Cancer Cells Utilize Macropinocytosis and Ubiquitin‐Proteasome System for Nutrient Acquisition

Wang,

Zhang,

Liu

et al. 2023

Advanced Science

View full text Add to dashboard Cite

To grow in nutrient‐deprived tumor microenvironment, cancer cells often internalize and degrade extracellular proteins to refuel intracellular amino acids. However, the nutrient acquisition routes reported by previous studies are mainly restricted in autophagy‐lysosomal pathway. It remains largely unknown if other protein degradation systems also contribute to the utilization of extracellular nutrients. Herein, it is demonstrated that under amino acid starvation, extracellular protein internalization through macropinocytosis and protein degradation through ubiquitin‐proteasome system are activated as a nutrient supply route, sensitizing cancer cells to proteasome inhibition. By inhibiting both macropinocytosis and ubiquitin‐proteasome system, an innovative approach to intensify amino acid starvation for cancer therapy is presented. To maximize therapeutic efficacy and minimize systemic side effects, a pH‐responsive polymersome nanocarrier is developed to deliver therapeutic agents specifically to tumor tissues. This nanoparticle system provides an approach to exacerbate amino acid starvation for cancer therapy, which represents a promising strategy for cancer treatment.

show abstract

Prognostic Role of the Ubiquitin Proteasome System in Clear Cell Renal Cell Carcinoma: A Bioinformatic Perspective

Cited by 7 publications

References 53 publications

Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications

Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications

Presence and possible impact of Fcγ receptors on resident kidney cells in health and disease

Amino Acid‐Starved Cancer Cells Utilize Macropinocytosis and Ubiquitin‐Proteasome System for Nutrient Acquisition

Contact Info

Product

Resources

About